A heart valve that grows with kids just won FDA approval

For a child born with a faulty pulmonary valve, open-heart surgery was never a one-time event. The valves surgeons could offer came in fixed sizes, and a growing body quickly outgrew them. In October 2026, the US Food and Drug Administration approved the first heart valve designed to solve that problem from the inside out: a device doctors can widen as a child grows, without opening the chest again.

The approval went to Edwards Lifesciences for a device developed by Autus Valve Technologies. Its formal name, the Autus Size-Adjustable Valve, replaces the pulmonary valve — the one-way gate that controls blood flow from the heart to the lungs — in children born with congenital defects of that valve. No heart valve had ever been cleared for expansion after surgery, according to reporting by The Priority Review.

Why children keep outgrowing a heart valve

Congenital heart defects touch about 1 in every 100 births in the United States, and two of them — pulmonary valve stenosis, in which the valve is narrowed, and pulmonary atresia, in which it fails to form properly — together affect around 4,200 babies a year, according to US birth-defect estimates cited by the FDA. Surgical repairs can leave the valve leaking blood backward, which over time can weaken or enlarge the heart's right ventricle.

Because a replacement valve does not grow, families and surgeons face a cruel timing call. Operate early, and the child will likely need several more open-heart operations as they get bigger; wait, and the heart can suffer lasting damage. Michelle Tarver, who directs the FDA's Center for Devices and Radiological Health, summed up the dilemma, saying that intervening too soon can mean multiple surgeries as a child grows, according to the agency's announcement.

How the expandable heart valve works

The new device starts small — surgeons can implant it as narrow as 13 millimeters across, a fit for a toddler or preschool child. Later, when growth demands a larger valve, a specialist threads a balloon catheter through a blood vessel and inflates it to widen the frame, up to 22 millimeters, a diameter comparable to an adult pulmonary valve. The expansion happens in a catheterization lab, not an operating room.

The materials are a breakthrough in their own right. The leaflets — the flaps that snap open and shut with every heartbeat — are made from a synthetic polymer rather than cow or pig tissue. Animal-tissue leaflets harden and break down faster in young patients, and one-year follow-up data suggest the polymer versions hold up better. The FDA had never cleared polymeric leaflets for any heart valve before this decision.

The idea has been a decade in the making. It began in a Boston Children's Hospital research lab, was tested in growing lambs, earned the FDA's Breakthrough Device designation, and moved through the agency's strictest review route for high-risk devices. It is also the first pediatric approval to come through the FDA's Total Product Life Cycle Advisory Program, which advises companies from early design through post-approval follow-up, as reported by Medical Design and Outsourcing.

What the heart valve study showed

The approval rests on a pivotal study of 62 children at 12 hospitals across the United States. Every heart valve implanted in the trial was placed successfully. Through 30 days, every patient was free of device-related complications, and through six months none needed a repeat procedure on the valve. There were no deaths, strokes, or blood clots requiring extra treatment, and at six months the first 60 patients evaluated had healthy blood flow through the right side of the heart with no more than mild backward leakage, according to Cardiovascular News.

For families, the promise is a calmer long-term plan. Emile Bacha, surgeon-in-chief at NewYork-Presbyterian/Columbia University Irving Medical Center and an investigator in the trial, called the device "a new way to think about long-term care planning" for patients who might otherwise face multiple surgeries, according to the Edwards announcement. Instead of scheduling the next open-heart operation the moment a child outgrows their implant, a care team could schedule a far gentler catheter procedure.

The valve decision lands amid a run of new options for young heart patients, including the first heart drug cleared for teens with a rare condition, as covered by GenZ NewZ. For more stories on medical breakthroughs, see our health coverage.

What we still don't know

There is an honest counterpoint to the excitement. The FDA also disclosed problems: the valve's metal frame fractured in three children, and in two others one leaflet did not move as freely as intended. None of those events caused symptoms, but they are a reminder that this is a first-generation device.

The bigger unknown is the very thing the valve was built for. Only two children in the study have actually had the device widened so far, and the FDA describes that experience as limited. The whole point of an expandable implant is to cut the number of operations across a childhood, yet that proof will take years to collect. Edwards says patients will be followed for a full decade to see whether expansions keep the valve working as promised.

Still, the direction of travel matters. Pediatric implants have long been an afterthought in medical design — the patient grows, but the device does not. A valve built with growth as part of the plan, rather than an obstacle to it, could spare young heart valve patients from some of the hardest operations in medicine. If the long-term data hold, the next heart valve implanted in a growing child may keep pace with them all the way to adulthood.